Completed

Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus

Sex Related Outcomes in Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A 12-month Real-world Study

Lead sponsor

University of Palermo

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

212

Study population

Type 2 diabetes

Eligibility highlights

•HbA1c ≥6.5%

Primary endpoint

•HbA1c, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07056803

Org study ID04

Timeline

Milestones

Study start2024-01-01actual

Primary completion2024-06-25actual

Study completion2025-06-25actual

Study first posted2025-07-09actual

Last update posted2025-07-17actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

This study investigated a population of adult outpatients with T2D diagnosed for at least 1 year, followed at the Endocrinology and Metabolism Division of the University Hospital of Palermo

Exclusion criteria

•pregnancy

•known allergy or hypersensitivity to semaglutide

•participation in another clinical trial during the treatment period

Inclusion criteria:

•age over 18 years

•diagnosis of T2D at least one year before the recruitment

•no treatment with prior GLP-1 RA

•baseline HbA1c >6.5% (48 mmol/mol)

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Number of participants with HbA1c change

Time frame:From enrollment to 12 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.